These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 31772768)

  • 1. Change of Vascular Endothelial Growth Factor Levels following Vitrectomy in Eyes with Proliferative Diabetic Retinopathy.
    Chen HJ; Ma ZZ; Li Y; Wang CG
    J Ophthalmol; 2019; 2019():6764932. PubMed ID: 31772768
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Persistent secretion of vascular endothelial growth factor into the vitreous cavity in proliferative diabetic retinopathy after vitrectomy.
    Itakura H; Kishi S; Kotajima N; Murakami M
    Ophthalmology; 2004 Oct; 111(10):1880-4. PubMed ID: 15465550
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vitreous mediators after intravitreal bevacizumab or triamcinolone acetonide in eyes with proliferative diabetic retinopathy.
    Arimura N; Otsuka H; Yamakiri K; Sonoda Y; Nakao S; Noda Y; Hashiguchi T; Maruyama I; Sakamoto T
    Ophthalmology; 2009 May; 116(5):921-6. PubMed ID: 19410951
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PERSISTENT OVERPRODUCTION OF INTRAOCULAR VASCULAR ENDOTHELIAL GROWTH FACTOR AS A CAUSE OF LATE VITREOUS HEMORRHAGE AFTER VITRECTOMY FOR PROLIFERATIVE DIABETIC RETINOPATHY.
    Wakabayashi Y; Usui Y; Tsubota K; Ueda S; Umazume K; Muramatsu D; Goto H
    Retina; 2017 Dec; 37(12):2317-2325. PubMed ID: 28098727
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vascular endothelial growth factor concentration in vitreous humor of patients with severe proliferative diabetic retinopathy after intravitreal injection of conbercept as an adjunctive therapy for vitrectomy.
    Li B; Li MD; Ye JJ; Chen Z; Guo ZJ; Di Y
    Chin Med J (Engl); 2020 Mar; 133(6):664-669. PubMed ID: 32068603
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness of prophylactic intravitreal bevacizumab injection to proliferative diabetic retinopathy patients with elevated preoperative intraocular VEGF in preventing complications after vitrectomy.
    Tsubota K; Usui Y; Wakabayashi Y; Suzuki J; Ueda S; Goto H
    Clin Ophthalmol; 2019; 13():1063-1070. PubMed ID: 31303746
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vascular endothelial growth factor in plasma and vitreous fluid of patients with proliferative diabetic retinopathy patients after intravitreal injection of bevacizumab.
    Ma Y; Zhang Y; Zhao T; Jiang YR
    Am J Ophthalmol; 2012 Feb; 153(2):307-313.e2. PubMed ID: 21982107
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vitreous and plasma concentrations of apelin and vascular endothelial growth factor after intravitreal bevacizumab in eyes with proliferative diabetic retinopathy.
    Qian J; Lu Q; Tao Y; Jiang YR
    Retina; 2011 Jan; 31(1):161-8. PubMed ID: 20890241
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intraocular VEGF level as a risk factor for postoperative complications after vitrectomy for proliferative diabetic retinopathy.
    Wakabayashi Y; Usui Y; Okunuki Y; Ueda S; Kimura K; Muramatsu D; Kezuka T; Goto H
    Invest Ophthalmol Vis Sci; 2012 Sep; 53(10):6403-10. PubMed ID: 22899753
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vitreous vascular endothelial growth factor concentrations in proliferative diabetic retinopathy versus proliferative vitreoretinopathy.
    Citirik M; Kabatas EU; Batman C; Akin KO; Kabatas N
    Ophthalmic Res; 2012; 47(1):7-12. PubMed ID: 21691136
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Level of Vascular Endothelial Growth Factor in the Vitreous Fluid of Proliferative Diabetic Retinopathy Patients and Prognosis after Vitrectomy.
    Suzuki Y; Suzuki K; Kudo T; Metoki T; Nakazawa M
    Ophthalmologica; 2016; 236(3):133-138. PubMed ID: 27794575
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reasons for and management of postvitrectomy vitreous hemorrhage in proliferative diabetic retinopathy.
    Yan H; Cui J; Lu Y; Yu J; Chen S; Xu Y
    Curr Eye Res; 2010 Apr; 35(4):308-13. PubMed ID: 20373898
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intravitreal bevacizumab for prevention of early postvitrectomy hemorrhage in diabetic patients: a randomized clinical trial.
    Ahmadieh H; Shoeibi N; Entezari M; Monshizadeh R
    Ophthalmology; 2009 Oct; 116(10):1943-8. PubMed ID: 19699531
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of a systemic angiotensin receptor blocker on vascular endothelial growth factor in the vitreous of patients with proliferative diabetic retinopathy.
    Byon IS; Jeon HS; Kim HW; Lee SJ; Lee JE; Oum BS
    Curr Eye Res; 2013 Jul; 38(7):774-80. PubMed ID: 23725216
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vitreous levels of angiopoietin 2 and vascular endothelial growth factor in patients with proliferative diabetic retinopathy.
    Watanabe D; Suzuma K; Suzuma I; Ohashi H; Ojima T; Kurimoto M; Murakami T; Kimura T; Takagi H
    Am J Ophthalmol; 2005 Mar; 139(3):476-81. PubMed ID: 15767056
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The impact of ranibizumab on the level of intercellular adhesion molecule type 1 in the vitreous of eyes with proliferative diabetic retinopathy.
    Yan Y; Zhu L; Hong L; Deng J; Song Y; Chen X
    Acta Ophthalmol; 2016 Jun; 94(4):358-64. PubMed ID: 26285163
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ghost cell glaucoma after intravitreal bevacizumab for postoperative vitreous hemorrhage following vitrectomy for proliferative diabetic retinopathy.
    Liu L; Wu WC; Yeung L; Wang NK; Kuo YH; Chao AN; Chen KJ; Chen TL; Lai CC; Hwang YS; Chen YP
    Ophthalmic Surg Lasers Imaging; 2010; 41(1):72-7. PubMed ID: 20128573
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vitreous levels of erythropoietin and vascular endothelial growth factor in eyes with retinopathy of prematurity.
    Sato T; Kusaka S; Shimojo H; Fujikado T
    Ophthalmology; 2009 Sep; 116(9):1599-603. PubMed ID: 19371954
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antiangiogenic shift in vitreous after vitrectomy in patients with proliferative diabetic retinopathy.
    Yoshida S; Nakama T; Ishikawa K; Arima M; Tachibana T; Nakao S; Sassa Y; Yasuda M; Enaida H; Oshima Y; Kono T; Ishibashi T
    Invest Ophthalmol Vis Sci; 2012 Oct; 53(11):6997-7003. PubMed ID: 22977138
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of intravitreal ranibizumab pretreatment on vitrectomy in young patients with proliferative diabetic retinopathy.
    Chen HJ; Wang CG; Dou HL; Feng XF; Xu YM; Ma ZZ
    Ann Palliat Med; 2020 Jan; 9(1):82-89. PubMed ID: 32005066
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.